Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for further gains. Analysts see 27% upside.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday.Analysts tracking the company see increased sales and profit for Eli Lilly in the first full period in which its weight-loss drugs ceased to be in shortage.
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of
Recent Research Analysts’ Ratings Updates for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) has recently received a number of price target changes and ratings updates: 2/3/2025 – Eli Lilly and Company had its price target raised by analysts at Truist Financial Co. from $1,029.00 to $1,038.00. They now have a “buy” rating on the stock.
Erste Group raises Eli Lilly stock rating to Buy, sees strong sales
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's significant sales growth expected this year along with a positive earnings outlook.
Eli Lilly Q4 2024 Earnings Preview: All eyes on stronger 2025
Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The consensus EPS Estimate is $5.11 (+105.2% Y/Y) and the consensus Revenue Estimate is $13.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
MM&M12h
Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
Eli Lilly and Company (LLY) Projected to Post Earnings on Thursday
Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Yahoo Finance5d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with ...
Aristotle Atlantic Focus Growth Strategy Increased its Holdings in Eli Lilly and Company (LLY)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...